GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marinus Pharmaceuticals Inc (NAS:MRNS) » Definitions » EPS without NRI

MRNS (Marinus Pharmaceuticals) EPS without NRI : $-2.44 (TTM As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Marinus Pharmaceuticals EPS without NRI?

Marinus Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Sep. 2024 was $-0.42. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.44.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 2.10% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 19.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Marinus Pharmaceuticals's EPS without NRI or its related term are showing as below:

MRNS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -112.2   Med: 9.3   Max: 49.5
Current: 2.1

During the past 12 years, Marinus Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 49.50% per year. The lowest was -112.20% per year. And the median was 9.30% per year.

MRNS's 3-Year EPS without NRI Growth Rate is ranked worse than
53.75% of 1213 companies
in the Biotechnology industry
Industry Median: 4.8 vs MRNS: 2.10

Marinus Pharmaceuticals's EPS (Diluted) for the three months ended in Sep. 2024 was $-0.42. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.47.

Marinus Pharmaceuticals's EPS (Basic) for the three months ended in Sep. 2024 was $-0.42. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.47.


Marinus Pharmaceuticals EPS without NRI Historical Data

The historical data trend for Marinus Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marinus Pharmaceuticals EPS without NRI Chart

Marinus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.97 -2.80 -2.69 -0.51 -2.63

Marinus Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.61 -0.74 -0.68 -0.60 -0.42

Competitive Comparison of Marinus Pharmaceuticals's EPS without NRI

For the Biotechnology subindustry, Marinus Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marinus Pharmaceuticals's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marinus Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Marinus Pharmaceuticals's PE Ratio without NRI falls into.



Marinus Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Marinus Pharmaceuticals  (NAS:MRNS) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Marinus Pharmaceuticals EPS without NRI Related Terms

Thank you for viewing the detailed overview of Marinus Pharmaceuticals's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Marinus Pharmaceuticals Business Description

Traded in Other Exchanges
Address
100 Matsonford Road, Suite 500, 5 Radnor Corporate Center, Radnor, PA, USA, 19087
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
Executives
Elan Ezickson director AVEO PHARMACEUTICALS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139
Marvin Johnson director C/O TREVENA, INC., 955 CHESTERBROOK BOULEVARD, STE. 110, CHESTERBROOK PA 19087
Scott Braunstein director C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Christina Shafer officer: Chief Commercial Officer 5 RADNOR CORPORATE CENTER, SUITE 500, 100 MATSONFORD ROAD, RADNOR PA 19087
Martha E Manning officer: VP, Gen. Counsel & Corp. Sec. 700 PENNSYLVANIA DR, EXTON PA 19341
Joseph Hulihan officer: Chief Medical Officer 5 RADNOR CORP CENTER SUITE 500, 100 MATSONFORD RD, RADNOR PA 19087
Steven Pfanstiel officer: CFO 5 RADNOR CORPORATE CENTER STE 500, 100 MATSONFORD RD, RADNOR PA 19087
Sarah B. Noonberg director 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Fischer Seth H.z. director C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Charles Austin director 5 RADNOR CORPORATE CENTER STE 500, 100 MATSONFORD RD, RADNOR PA 19087
Christine Berni Silverstein director C/O ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Santiago Arroyo director C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Sara Nochur director 295 WOODCLIFF RD, NEWTON MA 02461
Nicole Vitullo director, 10 percent owner 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Edward F Smith officer: Chief Financial Officer C/O POLYMEDIX, INC., 3701 MARKET STREET, PHILADELPHIA PA 19104